Amount of potential cash payments that could result from the contingent consideration arrangement.

Name:	us-gaap_BusinessAcquisitionContingentConsiderationPotentialCashPayment
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of cash paid to acquire the entity.

+ References

+ Details

Name:	us-gaap_BusinessAcquisitionCostOfAcquiredEntityCashPaid
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141

-Paragraph 51

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141

-Paragraph 24

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name:	us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Details

Name:	us-gaap_BusinessAcquisitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of voting equity interests acquired in the business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1392-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141R

-Paragraph 68

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name:	us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

This element represents the acquisition-date fair value of the total consideration transferred which consists of the sum of the acquisition-date fair values of the assets transferred by the acquirer, the liabilities incurred by the acquirer to former owners of the acquiree, and the equity interests issued by the acquirer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141R

-Paragraph 68

-Subparagraph f

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141R

-Paragraph 39, 40

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 30

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6613-128477

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 30

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6578-128477

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6927-128479

+ Details

Name:	us-gaap_BusinessCombinationConsiderationTransferred
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Cost of the investment.

+ References

No definition available.

+ Details

Name:	us-gaap_InvestmentOwnedAtCost
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(e))

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name:	us-gaap_LicenseCosts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of other deferred costs charged against earnings in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_OtherDeferredCostAmortizationExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Business development agreement potential cash payment.

+ References

No definition available.

+ Details

Name:	vphm_BusinessDevelopmentAgreementPotentialCashPayment
Namespace Prefix:	vphm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Expected Terms Of Option Agreement

+ References

No definition available.

+ Details

Name:	vphm_ExpectedTermsOfOptionAgreement
Namespace Prefix:	vphm_
Data Type:	xbrli:gYearMonthItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of additional milestone indications.

+ References

No definition available.

+ Details

Name:	vphm_NumberOfAdditionalMilestoneIndications
Namespace Prefix:	vphm_
Data Type:	xbrli:positiveIntegerItemType
Balance Type:	na
Period Type:	duration

- Definition

Payment Of Contingent Consideration

+ References

No definition available.

+ Details

Name:	vphm_PaymentOfContingentConsideration
Namespace Prefix:	vphm_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.

+ References

No definition available.

+ Details

Name:	vphm_RoyaltyExpensePercentage
Namespace Prefix:	vphm_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

Acquisitions, License and Research Agreements - Additional Information (Detail) In Millions, unless otherwise specified												9 Months Ended			1 Months Ended		9 Months Ended	1 Months Ended	9 Months Ended			3 Months Ended	9 Months Ended
	Nov. 15, 2011 Regulatory Milestones Maximum USD ($)	Nov. 15, 2011 Regulatory Milestones Maximum SEK	Nov. 15, 2011 Commercial Milestones Maximum USD ($)	Nov. 15, 2011 Commercial Milestones Maximum SEK	Nov. 15, 2011 DuoCort Pharma AB USD ($)	Nov. 15, 2011 DuoCort Pharma AB SEK	Jan. 01, 2011 DuoCort Pharma AB USD ($)	Nov. 15, 2011 DuoCort Pharma AB Maximum USD ($)	Nov. 15, 2011 DuoCort Pharma AB Maximum SEK	Nov. 15, 2011 DuoCort Pharma AB Minimum USD ($)	Nov. 15, 2011 DuoCort Pharma AB Minimum SEK	Sep. 30, 2012 Meritage Pharma Inc USD ($)	Dec. 22, 2011 Meritage Pharma Inc USD ($)	Dec. 22, 2011 Meritage Pharma Inc Maximum USD ($)	Sep. 30, 2011 Intellect Neurosciences Inc Up-Front Payment USD ($)	Sep. 30, 2011 Intellect Neurosciences Inc Additional Milestones USD ($)	Sep. 30, 2012 Halozyme Therapeutics Patent	May 31, 2011 Halozyme Therapeutics Up-Front Payment USD ($)	Sep. 30, 2012 Halozyme Therapeutics Additional Milestones USD ($)	Sep. 30, 2012 Halozyme Therapeutics HAE Milestone USD ($)	Sep. 30, 2012 Halozyme Therapeutics Annual Maintenance Fee USD ($)	Dec. 31, 2011 Halozyme Therapeutics Phase 2 Study Milestone Payment USD ($)	Sep. 30, 2011 Auralis Limited USD ($)	May 31, 2010 Auralis Limited USD ($)	May 31, 2010 Auralis Limited GBP (£)
Business Acquisition [Line Items]
Ownership interest					100.00%	100.00%																		100.00%	100.00%
Upfront cash payment of acquisition					$ 32.1	213.0																		$ 14.5
Contingent consideration, potential cash payment	24.0	160.0	107.0	700.0				131.0	860.0	37.0	240.0			175.0											10.0
Transaction cost incurred on acquisition							1.4
Investment cost												5.0	7.5
Business development agreement option exercised value of stock purchased													69.9
Expected term of option agreement												2014-12
Amortization expense												2.7
Business development agreement, potential cash payment												7.5
Licensing fee															6.5	120.0		9.0	30.0	41.0	1.0	3.0
Number of additional milestone indications																	3
Royalty on net sales of acquired combination product																	10.00%
Payment of contingent consideration																							$ 15.8